Tech Company Financing Transactions
Voyager Therapeutics Funding Round
Voyager Therapeutics, based in Cambridge, scored $60 million from Brookside Capital, Partner Fund Management and Casdin Capital.
Transaction Overview
Company Name
Announced On
4/13/2015
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Brookside Capital (Lead Investor) (Daniel Krizek)
Partner Fund Management (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to advance the company's product pipeline, which includes five clinical and preclinical programs, as well as its industry-leading adeno-associated virus (AAV) product engine.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
75 Sidney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Voyager Therapeutics (NASDAQ: VYGR) is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andre Turenne
Chief Scientific Officer
Dinah Sah
VP - Human Resources
Kathleen Hayes
VP - Regulatory Affairs
Robert Pietrusko
Browse more venture capital transactions:
Prev: 4/13/2015: Nabriva Therapeutics venture capital transaction
Next: 4/13/2015: Crowd Supply venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs